Dilazep


CAS No. : 35898-87-4

35898-87-4
Price and Availability of CAS No. : 35898-87-4
Size Price Stock
100 mg Get quote
250 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-100957A
M.Wt: 604.69
Formula: C31H44N2O10
Purity: >98 %
Solubility:
Introduction of 35898-87-4 :

Dilazep is a GATA2 inhibitor and an hENT1-mediated nucleoside transport inhibitor. Dilazep acts by blocking GATA2 chromatin recruitment and DNA binding, reducing GATA2 thermal stability, and inhibiting AR, c-MYC, the cell cycle, DNA replication/repair, and metastatic transcriptional programs; it also inhibits Adenosine (HY-B0228) reuptake and cardiac adenosine uptake, enhancing adenosine-induced coronary vasodilation. Dilazep can be used in research on atherosclerosis, ischemic heart disease, and castration-resistant prostate cancer[1][2][3][4][5][6][7]. In Vitro:Dilazep (50-100 µM; 16 hours) reduces GATA2 DNA binding in LNCaP nuclear extracts[6].
Dilazep (96 hours) inhibits the viability of GATA2-dependent LNCaP, LAPC4, Abl, 22Rv1, and MDVR prostate cancer cells, with lower activity in PC-3 and RWPE-1 cells[6].
Dilazep (50 µM; 48 hours) inhibits GATA2-, AR-, c-MYC-, cell cycle-, DNA repair-, stemness-, and metastasis-related transcriptional programs in LNCaP, Abl, and MDVR cells[6].
Dilazep (1-10 μM; from 5 minutes before ischemia to the end of 15-minute ischemia) reduces pre-ischemic RPP at 5 and 10 μM in isolated working rat hearts, but has no such effect at 1 μM, does not alter coronary flow, and improves post-ischemic recovery of RPP and coronary flow after 15-minute ischemia and 20-minute reperfusion[5].
Dilazep (20-50 µM; 24 hours) reduces S-phase entry in 22Rv1 and LNCaP cells[6].
Dilazep (1-10 μM; from 5 minutes before ischemia to the end of 15 minutes of ischemia) attenuates reperfusion-induced free fatty acid accumulation at 1, 5, and 10 μM in isolated working rat hearts, with 10 μM also reducing post-ischemic arachidonic acid (HY-109590)[5].
Dilazep (100 μM; 10 minutes to 24 hours) suppresses PpET-1 transcription to 0.04 normalized units at 24 h in subconfluent serum-treated BAEC and suppresses ET-1 peptide release to 38.8 pg/mL at 24 h[3].
Dilazep (12-24 hours) suppresses PpET-1 transcription to 0.47 at 12 hours in confluent serum-treated BAEC and suppresses ET-1 peptide release to 955.5 pg/mL at 12 hours[3].
Dilazep (1-100 μM; 16 hours) inhibits PpET-1 transcription in serum-treated BAEC in a concentration-dependent manner, reaching 0.42 at 100 μM after 16 hours[3].
Dilazep (100 μM; 3-6 hours) inhibits PpET-1 transcription to 0.41 at 3 hours and ET-1 peptide release to 299.0 pg/mL at 3 hours in serum-treated HUVECs[3].
Dilazep (100 μM; 0-4 hours) suppresses PpET-1 transcription to 0.30 at 1 hour and 0.08 at 2 hours in serum-deprived BAEC stimulated with Thrombin (MW 37kDa) (HY-114164)[3].
Dilazep (100 μM; 24 hours) inhibits ET-1 promoter activity by 99% at 24 hours in BAEC transfected with the 5-kb ET-1 promoter-luciferase construct[3].
Dilazep (1-10 μM; from 5 minutes before ischemia to the end of 15 minutes of ischemia) preserves ATP and CrP and reduces Lactic acid (HY-B2227) at 5 and 10 μM, but not at 1 μM, in isolated working rat hearts after 15 minutes of ischemia and 20 minutes of reperfusion[5].
Dilazep (1 nM-100 μM; ≥ 5 minutes) inhibits Uridine (HY-B1449) equilibrium exchange in erythrocytes, with an IC50 ≈ 7 nM in human erythrocytes, ≈ 20 nM in porcine erythrocytes, ≈ 30 nM in rabbit erythrocytes, ≈ 40 nM in mouse erythrocytes, and ≈ 1000 nM in rat erythrocytes[4].
Dilazep (50 µM; 48 hours) reduces AR, c-MYC, EZH2, RRM2, phosphorylated Rb, BRCA1, and CHK2 protein levels in LNCaP, Abl, and MDVR cells[6].
Dilazep (1 nM-100 μM; ≥ 5 min) inhibits zero-trans influx of uridine in cultured cells, with IC50 ≈ 5 nM in Hep-2, 5/3000 nM in HeLa, ≈ 10-30 nM in mouse L1210/P388/S49, ≈400 to >10000 nM in rat NRK/HTC/Novikoff/Walker 256, 20 nM in BHK, and 1000 nM in CHO cells[4].
Dilazep (10-50 µM; 72 hours) reduces AR and c-MYC protein levels in LNCaP, 22Rv1, and LAPC4 cells[6].
Dilazep (50 µM; 1 hour) binds to GATA2 in 22Rv1 cells, producing thermal destabilization with a Tm of 64-67°C[6].
Dilazep (10 µM; 16 hours) reduces GATA2 occupancy at the KLK3/PSA and c-MYC loci in LNCaP cells without reducing GATA2 protein[6].
Dilazep (10 µM; 24 hours) reduces GATA2-dependent PSA/KLK3 reporter activity in 22Rv1 cells[6].
Dilazep (10 μM; 4 days) blocks adenosine-rescued growth of wild-type hENT1 in hENT1-expressing W303-1A yeast, but has no such effect on the L92P mutant[7].
Dilazep (0.01-1000 nM; 20-minute preincubation, 20-minute uptake) inhibits [3H]adenosine transport, with an IC50 of 0.74 nM for wild-type hENT1 and an IC50 of 2.8 nM for L92Q in hENT1-expressing YPL1 yeast[7]. In Vivo:Dilazep (50 mg/kg; i.p.; daily 5 days per week (Monday-Friday)) inhibits MDA-PCa-337A castration-resistant prostate cancer PDX tumor growth in castrated SCID mice without causing body-weight loss[6].

Your information is safe with us.